Fondaparinux - A synthetic factor Xa inhibitor;Fondaparinux - Ein synthetischer faktor-Xa-inhibitor

Krankenhauspharmazie

Volumn 23, Issue 4, 2002, Pages 141-148

  Lipp, Hans Peter ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Comparative trials; Enoxaparin; Fondaparinux; Pharmacokinetics; Prophylaxis

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; FONDAPARINUX;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; ORTHOPEDIC SURGERY; POSTOPERATIVE PERIOD; PROPHYLAXIS; REVIEW; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0036231080     PISSN: 01737597     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Deep vein thrombosis and its prevention in critically ill adults
2. Production and clinical development of a Hansenula polymorpha-derived pegylated Hirudin
3. Fondaparinux compared with Enoxaparin for the prevention of venous thromboembolism after elective major knee surgery
4. A synthetic factor Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study
5. Choosing a parenteral anticoagulant agent
6. Thromboprophylaxis after replacement arthroplasty [Editorial]: Anticoagulants are more effective than aspirin
7. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia
8. Fondaparinux compared with Enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery
9. A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement
10. An update on hypercoagulable disorders
11. Randomized trial of low molecular weight heparin (Enoxaparin) versus unfractionated heparin for unstable coronary artery disease
12. Novel approaches to the treatment of thrombosis
13. Medizinische grundlagen und medico-legale aspekte der venösen thromboembolieprophylaxe
14. Prävention, diagnostik und therapie von thrombosen in der orthopädie und unfallchirurgie
15. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism
16. Fondaparinux-natrium - Ein neues antithrombotikum
17. Comparison of the oral direct thrombin inhibitor Ximelagatran with Enoxaparin as prophylaxis against venous thromboembolism after total knee replacement
18. Timing of initial administration of low-molecular-weight Heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty
19. Langzeitfolgen der tiefen beinvenenthrombose: Ihre wirtschaftliche bedeutung
20. Argatroban for prevention and treatment of thromboembolism in Heparin-induced thrombocytopenia
21. Severe pulmonary embolism associated with air travel
22. Fondaparinux versus Enoxaparin for the prevention of venous thromboembolism in elective hip replacement surgery. A randomised double-blind comparison
23. Production and chemical processing of low molecular weight heparins
24. Heparine, heparinoide und hirudin-derivate - Prophylaxe und therapie venöser thromboembolien
25. Argatroban
26. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina
27. Molecular weight measurements of low molecular weight Heparins by gel permeation chromatography
28. Leitlinien zur thromboembolie-prophylaxe
29. Novel design of peptides to reverse the anticoagulant activities of Heparin and other glycosaminoglycans
30. Genetic susceptibility to venous thrombosis
31. End points in studies on the prevention of deep vein thrombosis
32. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity
33. A synthetic pentasaccharide for the prevention of deep vein thrombosis after total hip replacement
34. Low-molecular-weight heparins in the treatment of acute coronary syndromes
35. A randomised double-blind comparison of Fondaparinux with Enoxaparin for the prevention of venous thromboembolism after elective hip replacement surgery
36. New data in treatment of acute coronary syndrome
37. Tempora aspects of Heparin-induced thrombocytopenia